- Home
- VFL vs BDSX Comparison
VFL vs BDSX Comparison
Compare VFL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFL
- BDSX
- Stock Information
- Founded
- VFL 1993
- BDSX 2005
- Country
- VFL United States
- BDSX United States
- Employees
- VFL N/A
- BDSX N/A
- Industry
- VFL Finance/Investors Services
- BDSX Precision Instruments
- Sector
- VFL Finance
- BDSX Health Care
- Exchange
- VFL Nasdaq
- BDSX Nasdaq
- Market Cap
- VFL 117.3M
- BDSX 115.4M
- IPO Year
- VFL N/A
- BDSX 2020
- Fundamental
- Price
- VFL $9.94
- BDSX $0.35
- Analyst Decision
- VFL
- BDSX Strong Buy
- Analyst Count
- VFL 0
- BDSX 4
- Target Price
- VFL N/A
- BDSX $2.83
- AVG Volume (30 Days)
- VFL 38.0K
- BDSX 523.2K
- Earning Date
- VFL 01-01-0001
- BDSX 05-13-2025
- Dividend Yield
- VFL 4.16%
- BDSX N/A
- EPS Growth
- VFL N/A
- BDSX N/A
- EPS
- VFL N/A
- BDSX N/A
- Revenue
- VFL N/A
- BDSX $71,323,000.00
- Revenue This Year
- VFL N/A
- BDSX $32.90
- Revenue Next Year
- VFL N/A
- BDSX $24.65
- P/E Ratio
- VFL N/A
- BDSX N/A
- Revenue Growth
- VFL N/A
- BDSX 45.30
- 52 Week Low
- VFL $7.93
- BDSX $0.45
- 52 Week High
- VFL $10.77
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- VFL 53.33
- BDSX 27.69
- Support Level
- VFL $9.87
- BDSX $0.51
- Resistance Level
- VFL $10.13
- BDSX $0.58
- Average True Range (ATR)
- VFL 0.12
- BDSX 0.06
- MACD
- VFL 0.05
- BDSX -0.01
- Stochastic Oscillator
- VFL 70.77
- BDSX 1.15
About VFL abrdn National Municipal Income Fund
Delaware Investments Natl Muni Income is a closed-end investment fund. The Fund seeks to provide current income exempt from regular federal income tax consistent with the preservation of capital. The company's product portfolio includes Mutual funds, Exchange-traded funds, Private markets, Delaware Funds by Macquarie Premier Models, Managed accounts, Closed-end funds, and Variable Insurance Products.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.